Photodynamic therapy (PDT) is a treatment modality where light-mediated activation of
photosensitizers in a patient's body leads to the generation of cytotoxic reactive oxygen …

The human epidermal growth factor receptor (HER) family of receptor tyrosine kinases plays
an important role in the biology of many cancers. In breast and gastrointestinal cancer, and …

Although Michael acceptors display a potent and broad spectrum of bioactivity, they have
largely been ignored in drug discovery because of their presumed indiscriminate reactivity …

Constitutive activation of signal transducer and activator of transcription 3 (STAT3) is a
common feature in human non-small cell lung cancer (NSCLC). STAT3 plays an important …

Over the past decade, first and second generation EGFR inhibitors have significantly
improved outcomes for lung cancer patients with activating mutations in EGFR. However …

In spite of the increasing number of biologics license applications, the development of
covalent inhibitors is still a growing field within drug discovery. The successful approval of …

CAR-modified T cells show impressive results in clinical trials. However, cytokine release
syndrome and “on-target, off-tumor” reactions represent most concerning side effects. To …

Brain metastases (BM) are a common and lethal complication of non-small cell lung cancer
(NSCLC), which portend a poor prognosis. In addition, their management implies several …

Gefitinib, as the first-generation epidermal growth factor receptor tyrosine kinase inhibitor
(EGFR-TKI), has achieved great advances in the treatment of non-small cell lung cancer …

The anaplastic lymphoma tyrosine kinase (ALK) gene was first described as a driver
mutation in anaplastic non-Hodgkin's lymphoma. Dysregulated ALK expression is now an …